The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 2, 2012, Pages 132-137

  Gladstone, Douglas E ^a   Blackford, Amanda ^a   Cho, Eunpi ^a   Swinnen, Lode ^a   Kasamon, Yvette ^a   Gocke, Christopher D ^a   Griffin, Constance A ^a   Bolaños Meade, Javier ^a   Jones, Richard J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Clinical outcomes; CLL; del(11q); del(17p); IGHV

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; BENDAMUSTINE; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OFATUMUMAB; PENTOSTATIN; RITUXIMAB;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER PATIENT; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POINT MUTATION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84858959090     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.12.005     Document Type: Article

References (13)

1. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-6. (Pubitemid 32064784)
2. Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009; 114:957-64.
3. Tomomatsu J, Isobe Y, Oshimi K, et al. Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior. Leuk Lymphoma 2010; 51:2230-9.
4. Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 2009; 23:212-4.
5. Gladstone DE, Swinnen L, Kasamon Y, et al. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. Leuk Lymphoma 2011; 52:1873-81.
6. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840-7. (Pubitemid 29430399)
7. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848-54. (Pubitemid 29430400)
8. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99:1023-9. (Pubitemid 34525567)
9. Kharfan-Dabaja MA, Chavez JC, Khorfan KA, et al. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer 2008; 113:897-906.
10. Trojani A, Montillo M, Nichelatti M, et al. ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia. Cancer Biomark 2010; 6:1-9.
11. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007; 370:230-9. (Pubitemid 47069536)
12. Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116:2438-47.
13. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008; 26:5094-100.